Statement: the secondary clinical trial documents the overall survival (os) of patients in its researched groups.
Primary_evidence: Outcome Measurement:    LDex Change-   Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases.   Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks. Results 1:    Arm/Group Title: Laser Therapy Alone   Arm/Group Description: therapist administered laser treatment   laser: therapist administered laser   Overall Number of Participants Analyzed: 15   Median (Inter-Quartile Range)   Unit of Measure: LDex  28.0        (17 to 35) Results 2:    Arm/Group Title: Mld Alone   Arm/Group Description: therapist administered manual lymphatic drainage   manual lymphatic drainage: therapist administered massage therapy   Overall Number of Participants Analyzed: 16   Median (Inter-Quartile Range)   Unit of Measure: LDex  17.8        (3 to 38)
Secondary_evidence: Outcome Measurement:    Overall Survival (OS) of Patients   To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis.   Time frame: Within 3 years from study start Results 1:    Arm/Group Title: NKTR-102   Arm/Group Description: In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.   Overall Number of Participants Analyzed: 92   Median (95% Confidence Interval)   Unit of Measure: months  7.8        (6.1 to 10.2) Results 2:    Arm/Group Title: Treatment of Physician's Choice (TPC)   Arm/Group Description: In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.   Overall Number of Participants Analyzed: 86   Median (95% Confidence Interval)   Unit of Measure: months  7.5        (5.8 to 10.4)